Boniva Gets A Second, Truncated 30-Month Stay
This article was originally published in The Pink Sheet Daily
Executive Summary
Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.
You may also be interested in...
Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane
A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.
Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane
A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.
Court Rules Apotex, Cobalt Infringe Roche's Boniva Patent
A New Jersey district court judge trounces the generic manufacturers' claim that the salt of the drug's active ingredient is not physiologically active.